category,datetime,headline,id,image,related,source,summary,url
company,1768429020,Biomerica Reports Second Quarter Fiscal 2026 Financial Results,138116223,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,HSIC,Yahoo,"Operating Expenses Decline 4% Year-to-DateBalance Sheet Strengthens and Working Capital Improves by 14.7% IRVINE, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2026 ended November 30, 2025. Key Highlights: 1.Biomerica Expands Commercialization of inFoods® IBS Through Collaboration with Henry Schein During the secon",https://finnhub.io/api/news?id=dae90372f482d0f2c95fcfb9eb985de76e58641c6b4cb3adc636552f929502ad
company,1768426252,"Henry Schein, Inc. (HSIC) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow",138116899,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,HSIC,SeekingAlpha,"2026-01-14. The following slide deck was published by Henry Schein, Inc.",https://finnhub.io/api/news?id=201858b69ea215e120d961801894f63bc26de048643980d3b6c664da9e562bed
company,1768415253,"JPM26: Henry Schein focuses on high-margin, high-growth business as new CEO announced",138114624,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,HSIC,Yahoo,Henry Schein currently has a broad portfolio with over $3bn in corporate and owned brand products and services.,https://finnhub.io/api/news?id=7ee985533bc4bf3a7e9a2d3d3b2ad260ee3ddeb115a9625a426ce1427435a5bd
